Regeneron Pharmaceuticals Inc. (REGN)

399.14
NASDAQ : Health Technology
Prev Close 400.81
Day Low/High 393.76 / 401.08
52 Wk Low/High 271.37 / 442.00
Avg Volume 772.00K
Exchange NASDAQ
Shares Outstanding 108.17M
Market Cap 44.10B
EPS 19.40
P/E Ratio 21.71
Div & Yield N.A. (N.A)
Even Stocks With Bullish Outlooks Are Not Safe in the Market Carnage

Even Stocks With Bullish Outlooks Are Not Safe in the Market Carnage

Which means interest rate hikes are being built into prices.

Regeneron Shows a High Volume Bottom

Regeneron Shows a High Volume Bottom

Regeneron shows its relative strength in the market selloff.

How China's Troubles Affect Biotech and Pharma Stocks: Part 1

How China's Troubles Affect Biotech and Pharma Stocks: Part 1

At first glance there is little connection, but you need to look deeper.

Odds Are Regeneron Rally Can Continue

Odds Are Regeneron Rally Can Continue

My maximum risk can be defined below the July 27 low.

Finally, Respite From the Volatility

Finally, Respite From the Volatility

Still, momentum is cooling and valuation is an issue in more cases.

Stocks With Significant High Activity: the First Four Groups

Stocks With Significant High Activity: the First Four Groups

There are some good buying ideas among these stocks.

The Market Reacts Rationally for Once

High-growth names, big commodity-takers, consumer plays shine today.

You Can Run, But You Can't Hide Today

There's no such thing as a 'safe harbor' right now on Wall Street.

Jim Cramer Won't Turn on Apple, Doesn't Like Twitter Until $19.20

Jim Cramer Won't Turn on Apple, Doesn't Like Twitter Until $19.20

Jim Cramer answers viewers' Twitter questions from the floor of the New York Stock Exchange.

Futures Tick Higher; Obama Pushes Emissions Reductions

Futures Tick Higher; Obama Pushes Emissions Reductions

Coal and renewables could both react as political and legal battles ensue.

Cramer: Biogen's Horseman May Have Fallen Off, I Like Others More

Cramer: Biogen's Horseman May Have Fallen Off, I Like Others More

TheStreet's Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange.

When Leader Goes Down, Whole Sector Feels It

Biogen's weak numbers leave biotechs ailing.

Are Any New FANGs Baring Their Teeth?

Are Any New FANGs Baring Their Teeth?

The fearsome foursome have been reborn.

Cramer: Own Starbucks Over Dunkin, PayPal IPO Is a Buy Right Now

Cramer: Own Starbucks Over Dunkin, PayPal IPO Is a Buy Right Now

Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange.

iShares Nasdaq Biotech ETF is Just What the Doctor Ordered for Your Portfolio

iShares Nasdaq Biotech ETF is Just What the Doctor Ordered for Your Portfolio

Technical factors point to a looming breakout for IBB.

Regeneron Reaches a Great Entry Point

Regeneron Reaches a Great Entry Point

This could be an opportune price to buy REGN, as it allows you to take a position fairly close to well-defined support.

Biotech Moves Are Anything But Crazy

New companies are coming up with major drugs.

A Stellar Day. But Why?

Bulls have the upper hand again.

Playing Biotechs with the House's Money

Playing Biotechs with the House's Money

Here's how to lock in gains on risky small-cap biotechnology stocks.

Cramer: Intel Had to Be Aggressive With Altera, Don't Sell Amgen

Cramer: Intel Had to Be Aggressive With Altera, Don't Sell Amgen

Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange.

What's Wrong With Betting on One Stock?

What's Wrong With Betting on One Stock?

'Single-stock risk' is all the rage these days.

Why I'm Looking at Biotechs, Not Airlines

Cutthroat competition is good for customers, but not shareholders.

3 Biotechs That Are Worth Buying

Many of these stocks are off to the races.

The Second-Strongest Stock Market Sector Doesn't Jibe With the Strongest

The Second-Strongest Stock Market Sector Doesn't Jibe With the Strongest

You could throw darts at financials and health care and win. 

Where to Invest to Shelter From the Market Rotation Crossfire

Some companies are so strong that they buck the rotation.

Cramer: I Like Receptos and Radius, as Well as the Four Horsemen

Cramer: I Like Receptos and Radius, as Well as the Four Horsemen

Jim Cramer answers viewers' stock questions from the floor of the New York Stock Exchange.

Janet Yellen, Stock Market Commentator?

It's not the Fed chief's place.

Here's What's Driving Biotech

And it's not the favorable macroeconomic climate.

I'm Going to Keep Riding These Horses

Biogen miss no reason to abandon big 4 of Big Pharma.